肺癌中的表皮生长因子受体靶向治疗：疗效和毒性的预测指标
EGFR-targeted therapies in lung cancer: predictors of response and toxicity.
作者信息
Heist Rebecca Suk, Christiani David
机构信息
Massachusetts General Hospital/Harvard Medical School, Yawkey 7B, 55 Fruit Street, Boston, MA 02114, USA.
出版信息
Pharmacogenomics. 2009 Jan;10(1):59-68. doi: 10.2217/14622416.10.1.59.
Abstract
The EGFR pathway has emerged as a key target in non-small-cell lung cancer. EGF receptor (EGFR) inhibition in non-small-cell lung cancer is achieved via small molecular tyrosine kinase inhibitors, such as erlotinib or gefitinib, or monoclonal antibodies such as cetuximab. A growing body of evidence is identifying potential molecular predictors of response and toxicity. This includes tumor-related molecular markers, such as EGFR mutation and copy number, as well as germline markers such as polymorphisms in EGFR or EGFR pathway-related genes. This review focuses on the current state of knowledge of predictors of response and toxicity to EGFR inhibitors in lung cancer.
摘要
表皮生长因子受体（EGFR）通路已成为非小细胞肺癌的关键靶点。在非小细胞肺癌中，通过小分子酪氨酸激酶抑制剂（如厄洛替尼或吉非替尼）或单克隆抗体（如西妥昔单抗）来实现对表皮生长因子受体（EGFR）的抑制。越来越多的证据正在确定反应和毒性的潜在分子预测指标。这包括肿瘤相关分子标志物，如EGFR突变和拷贝数，以及种系标志物，如EGFR或EGFR通路相关基因的多态性。本综述重点关注肺癌中EGFR抑制剂反应和毒性预测指标的当前知识状态。
相似文献
1
EGFR-targeted therapies in lung cancer: predictors of response and toxicity.肺癌中的表皮生长因子受体靶向治疗：疗效和毒性的预测指标
Pharmacogenomics. 2009 Jan;10(1):59-68. doi: 10.2217/14622416.10.1.59.
2
Personalized medicine in non-small-cell lung cancer: is KRAS a useful marker in selecting patients for epidermal growth factor receptor-targeted therapy?非小细胞肺癌的个体化医学：KRAS 是否是选择表皮生长因子受体靶向治疗患者的有用标志物？
J Clin Oncol. 2010 Nov 1;28(31):4769-77. doi: 10.1200/JCO.2009.27.4365. Epub 2010 Oct 4.
3
Role of tyrosine kinase inhibitors in lung cancer.酪氨酸激酶抑制剂在肺癌中的作用。
Anticancer Agents Med Chem. 2009 Jun;9(5):569-75. doi: 10.2174/187152009788451879.
4
First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.晚期表皮生长因子受体（EGFR）突变阳性非鳞状非小细胞肺癌的一线治疗。
Cochrane Database Syst Rev. 2021 Mar 18;3(3):CD010383. doi: 10.1002/14651858.CD010383.pub3.
5
Targeted therapy for the treatment of non-small cell lung cancer: focus on inhibition of epidermal growth factor receptor.非小细胞肺癌治疗的靶向疗法：聚焦于表皮生长因子受体抑制
Semin Thorac Cardiovasc Surg. 2008 Fall;20(3):217-23. doi: 10.1053/j.semtcvs.2008.09.005.
6
First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.晚期表皮生长因子受体（EGFR）突变阳性非鳞状非小细胞肺癌的一线治疗
Cochrane Database Syst Rev. 2016 May 25(5):CD010383. doi: 10.1002/14651858.CD010383.pub2.
7
Inhibition of the epidermal growth factor receptor in combined modality treatment for locally advanced non-small cell lung cancer.表皮生长因子受体抑制在局部晚期非小细胞肺癌综合治疗中的应用
Semin Oncol. 2005 Apr;32(2 Suppl 3):S35-41. doi: 10.1053/j.seminoncol.2005.03.008.
8
Targeting the epidermal growth factor receptor in non-small cell lung cancer cells: the effect of combining RNA interference with tyrosine kinase inhibitors or cetuximab.针对非小细胞肺癌细胞中的表皮生长因子受体：RNA 干扰与酪氨酸激酶抑制剂或西妥昔单抗联合的效果。
BMC Med. 2012 Mar 21;10:28. doi: 10.1186/1741-7015-10-28.
9
Establishment of patient-derived non-small cell lung cancer xenografts as models for the identification of predictive biomarkers.建立患者来源的非小细胞肺癌异种移植模型用于预测生物标志物的鉴定。
Clin Cancer Res. 2008 Oct 15;14(20):6456-68. doi: 10.1158/1078-0432.CCR-08-0138.
10
[Molecular diagnostics in lung carcinoma for therapy stratification].
Pathologe. 2010 Feb;31(1):22-8. doi: 10.1007/s00292-009-1241-1.
引用本文的文献
1
Bispecific Siglec-15/T cell antibody (STAB) activates T cells and suppresses pancreatic ductal adenocarcinoma and non-small cell lung tumors .双特异性唾液酸结合免疫球蛋白样凝集素15/T细胞抗体（STAB）可激活T细胞并抑制胰腺导管腺癌和非小细胞肺癌肿瘤。
Theranostics. 2025 Apr 13;15(12):5529-5542. doi: 10.7150/thno.103372. eCollection 2025.
2
Prevalence of single-nucleotide variants in twenty-five pharmacogenes from a Cuban sample cohort.古巴样本队列中25个药物代谢基因的单核苷酸变异患病率
Front Pharmacol. 2024 Sep 27;15:1467036. doi: 10.3389/fphar.2024.1467036. eCollection 2024.
3
In Silico and In Vitro Exploration of Poziotinib and Olmutinib Synergy in Lung Cancer: Role of hsa-miR-7-5p in Regulating Apoptotic Pathway Marker Genes.在肺癌中探索波齐替尼和奥卢米替尼的协同作用：hsa-miR-7-5p 在调节细胞凋亡途径标记基因中的作用。
Medicina (Kaunas). 2023 Oct 30;59(11):1923. doi: 10.3390/medicina59111923.
4
Human Blood Serum Can Diminish EGFR-Targeted Inhibition of Squamous Carcinoma Cell Growth through Reactivation of MAPK and EGFR Pathways.人血清可通过重新激活 MAPK 和 EGFR 通路减弱表皮生长因子受体靶向抑制剂对鳞癌细胞生长的抑制作用。
Cells. 2023 Aug 8;12(16):2022. doi: 10.3390/cells12162022.
5
Zero-Background Small-Molecule Sensors for Near-IR Fluorescent Imaging of Biomacromolecular Targets in Cells.用于细胞内生物大分子靶标近红外荧光成像的零背景小分子传感器。
ACS Sens. 2023 Mar 24;8(3):1109-1118. doi: 10.1021/acssensors.2c02342. Epub 2023 Mar 3.
6
Immunotherapy and targeted therapy for lung cancer: Current status and future perspectives.肺癌的免疫疗法和靶向疗法：现状与未来展望。
Front Pharmacol. 2022 Nov 28;13:1035171. doi: 10.3389/fphar.2022.1035171. eCollection 2022.
7
Emerging genetic biomarkers in lung adenocarcinoma.肺腺癌中新兴的基因生物标志物
SAGE Open Med. 2022 Oct 18;10:20503121221132352. doi: 10.1177/20503121221132352. eCollection 2022.
8
Impact of heavy smoking on the benefits from first-line EGFR-TKI therapy in patients with advanced lung adenocarcinoma.重度吸烟对晚期肺腺癌患者一线表皮生长因子受体酪氨酸激酶抑制剂（EGFR-TKI）治疗获益的影响
Medicine (Baltimore). 2018 Mar;97(9):e0006. doi: 10.1097/MD.0000000000010006.
9
IL6 is associated with response to dasatinib and cetuximab: Phase II clinical trial with mechanistic correlatives in cetuximab-resistant head and neck cancer.白细胞介素6与达沙替尼和西妥昔单抗的疗效相关：针对西妥昔单抗耐药的头颈癌的II期临床试验及机制相关性研究
Oral Oncol. 2017 Jun;69:38-45. doi: 10.1016/j.oraloncology.2017.03.011. Epub 2017 Apr 9.
10
Emerging Roles of MicroRNAs in EGFR-Targeted Therapies for Lung Cancer.微小RNA在肺癌表皮生长因子受体靶向治疗中的新作用
Biomed Res Int. 2015;2015:672759. doi: 10.1155/2015/672759. Epub 2015 Jul 26.
本文引用的文献
1
Gefitinib in advanced non-small cell lung cancer: does it deserve a second chance?吉非替尼用于晚期非小细胞肺癌：它值得再次尝试吗？
Oncologist. 2008 Sep;13(9):933-44. doi: 10.1634/theoncologist.2008-0019. Epub 2008 Sep 10.
2
Phase III study, V-15-32, of gefitinib versus docetaxel in previously treated Japanese patients with non-small-cell lung cancer.吉非替尼与多西他赛对比用于既往接受过治疗的日本非小细胞肺癌患者的III期研究，V-15-32
J Clin Oncol. 2008 Sep 10;26(26):4244-52. doi: 10.1200/JCO.2007.15.0185.
3
Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21.在加拿大国家癌症研究所临床试验组BR.21研究中，KRAS和EGFR作为厄洛替尼反应生物标志物的作用
J Clin Oncol. 2008 Sep 10;26(26):4268-75. doi: 10.1200/JCO.2007.14.8924. Epub 2008 Jul 14.
4
Increased EGFR gene copy number detected by fluorescent in situ hybridization predicts outcome in non-small-cell lung cancer patients treated with cetuximab and chemotherapy.通过荧光原位杂交检测到的表皮生长因子受体（EGFR）基因拷贝数增加可预测接受西妥昔单抗和化疗的非小细胞肺癌患者的预后。
J Clin Oncol. 2008 Jul 10;26(20):3351-7. doi: 10.1200/JCO.2007.14.0111.
5
A polymorphism of EGFR extracellular domain is associated with progression free-survival in metastatic colorectal cancer patients receiving cetuximab-based treatment.表皮生长因子受体（EGFR）胞外域的一种多态性与接受西妥昔单抗治疗的转移性结直肠癌患者的无进展生存期相关。
BMC Cancer. 2008 Jun 10;8:169. doi: 10.1186/1471-2407-8-169.
6
First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations.一线使用吉非替尼治疗携带体细胞EGFR突变的晚期非小细胞肺癌患者。
J Clin Oncol. 2008 May 20;26(15):2442-9. doi: 10.1200/JCO.2007.14.8494. Epub 2008 May 5.
7
Pharmacogenetic profiling for cetuximab plus irinotecan therapy in patients with refractory advanced colorectal cancer.西妥昔单抗联合伊立替康治疗难治性晚期结直肠癌患者的药物遗传学分析
J Clin Oncol. 2008 Mar 20;26(9):1427-34. doi: 10.1200/JCO.2007.12.4602.
8
EGFR antagonists in cancer treatment.癌症治疗中的表皮生长因子受体拮抗剂
N Engl J Med. 2008 Mar 13;358(11):1160-74. doi: 10.1056/NEJMra0707704.
9
Pharmacogenomic and pharmacokinetic determinants of erlotinib toxicity.厄洛替尼毒性的药物基因组学和药代动力学决定因素。
J Clin Oncol. 2008 Mar 1;26(7):1119-27. doi: 10.1200/JCO.2007.13.1128.
10
Multicentre prospective phase II trial of gefitinib for advanced non-small cell lung cancer with epidermal growth factor receptor mutations: results of the West Japan Thoracic Oncology Group trial (WJTOG0403).吉非替尼用于治疗表皮生长因子受体突变的晚期非小细胞肺癌的多中心前瞻性II期试验：日本西部胸部肿瘤学组试验（WJTOG0403）结果
Br J Cancer. 2008 Mar 11;98(5):907-14. doi: 10.1038/sj.bjc.6604249. Epub 2008 Feb 19.
Zotero 插件